{"transactions":[{"id":1805864,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":26400,"derivative":{"exercise_price":2.14,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805863,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805862,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805861,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805860,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":1172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on December 1, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":1172,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":1172},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805859,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on December 1, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":1172},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805858,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805857,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805856,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% of the shares subject to this option vested and became exercisable on December 1, 2021, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":28828,"derivative":{"exercise_price":2.14,"expiration_date":"2030-11-30","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1805855,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:08:23.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% of the shares subject to this option vested and became exercisable on December 1, 2021, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2030-11-30","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0001209191-23-046097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046097/doc4.xml","form_type":"4"}},{"id":1870048,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:49:28.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-033960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123033960/doc4.xml","form_type":"4"}},{"id":1870047,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:49:28.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":5900,"source":{"system":"sec-edgar","filing":"0001209191-23-033960","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123033960/doc4.xml","form_type":"4"}},{"id":349333,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-09T20:15:20.000Z","date":"2023-05-08","kind":"sale","planned":true,"acquired":false,"shares":2850,"price":350,"value":997500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."}],"balance_after":32038,"source":{"system":"sec-edgar","filing":"0001209191-23-028243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123028243/doc4.xml","form_type":"4"}},{"id":349332,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-09T20:15:20.000Z","date":"2023-05-05","kind":"sale","planned":true,"acquired":false,"shares":422,"price":350.03,"value":147712.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40)."}],"balance_after":34888,"source":{"system":"sec-edgar","filing":"0001209191-23-028243","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123028243/doc4.xml","form_type":"4"}},{"id":349434,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-04T20:51:48.000Z","date":"2023-05-03","kind":"sale","planned":true,"acquired":false,"shares":728,"price":351.6,"value":255964.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $351.60 (range $351.01 to $352.00)."}],"balance_after":35310,"source":{"system":"sec-edgar","filing":"0001209191-23-027374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027374/doc4.xml","form_type":"4"}},{"id":349433,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-04T20:51:48.000Z","date":"2023-05-03","kind":"sale","planned":true,"acquired":false,"shares":2053,"price":350.44,"value":719453.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $350.44 (range $350.00 to $350.94)."}],"balance_after":36038,"source":{"system":"sec-edgar","filing":"0001209191-23-027374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027374/doc4.xml","form_type":"4"}},{"id":349432,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-04T20:51:48.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":169,"price":353.24,"value":59697.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $353.24 (range $353.21 to $353.49)."}],"balance_after":38091,"source":{"system":"sec-edgar","filing":"0001209191-23-027374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027374/doc4.xml","form_type":"4"}},{"id":349431,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-04T20:51:48.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":42,"price":351.65,"value":14769.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $351.65 (range $351.48 to $351.80)."}],"balance_after":38260,"source":{"system":"sec-edgar","filing":"0001209191-23-027374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027374/doc4.xml","form_type":"4"}},{"id":349430,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-05-04T20:51:48.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":1411,"price":350.32,"value":494301.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $350.32 (range $350.00 to $350.92)."}],"balance_after":38302,"source":{"system":"sec-edgar","filing":"0001209191-23-027374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027374/doc4.xml","form_type":"4"}},{"id":350297,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-14T20:19:24.000Z","date":"2023-04-12","kind":"sale","planned":true,"acquired":false,"shares":2625,"price":327.43,"value":859503.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91)."}],"balance_after":39713,"source":{"system":"sec-edgar","filing":"0001209191-23-024312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123024312/doc4.xml","form_type":"4"}},{"id":350296,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-14T20:19:24.000Z","date":"2023-04-12","kind":"sale","planned":true,"acquired":false,"shares":4068,"price":326.45,"value":1327998.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99)."}],"balance_after":42338,"source":{"system":"sec-edgar","filing":"0001209191-23-024312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123024312/doc4.xml","form_type":"4"}},{"id":350295,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-14T20:19:24.000Z","date":"2023-04-12","kind":"sale","planned":true,"acquired":false,"shares":874,"price":325.7,"value":284661.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98)."}],"balance_after":46406,"source":{"system":"sec-edgar","filing":"0001209191-23-024312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123024312/doc4.xml","form_type":"4"}},{"id":350357,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-06T20:23:35.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":31,"price":318.68,"value":9879.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."}],"balance_after":47280,"source":{"system":"sec-edgar","filing":"0001209191-23-023588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123023588/doc4.xml","form_type":"4"}},{"id":350356,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-06T20:23:35.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":96,"price":317.65,"value":30494.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $317.65 (range $317.49 to $317.74)."}],"balance_after":47311,"source":{"system":"sec-edgar","filing":"0001209191-23-023588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123023588/doc4.xml","form_type":"4"}},{"id":350355,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-06T20:23:35.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":90,"price":316.76,"value":28508.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $316.76 (range $316.41 to $317.20)."}],"balance_after":47407,"source":{"system":"sec-edgar","filing":"0001209191-23-023588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123023588/doc4.xml","form_type":"4"}},{"id":350354,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-06T20:23:35.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":94,"price":315.66,"value":29672.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $315.66 (range $315.08 to $315.96)."}],"balance_after":47497,"source":{"system":"sec-edgar","filing":"0001209191-23-023588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123023588/doc4.xml","form_type":"4"}},{"id":350353,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-06T20:23:35.000Z","date":"2023-04-04","kind":"sale","planned":true,"acquired":false,"shares":211,"price":314.22,"value":66300.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $314.22 (range $313.72 to $314.70)."}],"balance_after":47591,"source":{"system":"sec-edgar","filing":"0001209191-23-023588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123023588/doc4.xml","form_type":"4"}},{"id":350478,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-04-04T20:20:11.000Z","date":"2023-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1466,"price":313.74,"value":459942.84,"ownership":{"direct":true},"balance_after":47802,"source":{"system":"sec-edgar","filing":"0001209191-23-022695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123022695/doc4.xml","form_type":"4"}},{"id":351035,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-03-20T20:26:33.000Z","date":"2023-03-16","kind":"sale","planned":true,"acquired":false,"shares":264,"price":301.07,"value":79482.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $301.07 (range $301.00 to $301.14)."}],"balance_after":49268,"source":{"system":"sec-edgar","filing":"0001209191-23-020043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123020043/doc4.xml","form_type":"4"}},{"id":351034,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-03-20T20:26:33.000Z","date":"2023-03-16","kind":"sale","planned":true,"acquired":false,"shares":2482,"price":300.54,"value":745940.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $300.54 (range $300.00 to $300.94)."}],"balance_after":49532,"source":{"system":"sec-edgar","filing":"0001209191-23-020043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123020043/doc4.xml","form_type":"4"}},{"id":352326,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-28T22:09:01.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":3970,"price":289.12,"value":1147806.4,"ownership":{"direct":true},"balance_after":52014,"source":{"system":"sec-edgar","filing":"0001209191-23-013757","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013757/doc4.xml","form_type":"4"}},{"id":352889,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-22T21:46:35.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":3750,"price":292.85,"value":1098187.5,"ownership":{"direct":true},"balance_after":55984,"source":{"system":"sec-edgar","filing":"0001209191-23-011701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011701/doc4.xml","form_type":"4"}},{"id":353266,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-16T21:16:05.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":279,"price":301.11,"value":84009.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22)."}],"balance_after":59734,"source":{"system":"sec-edgar","filing":"0001209191-23-010055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010055/doc4.xml","form_type":"4"}},{"id":353265,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-16T21:16:05.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":1902,"price":300.29,"value":571151.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92)."}],"balance_after":60013,"source":{"system":"sec-edgar","filing":"0001209191-23-010055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010055/doc4.xml","form_type":"4"}},{"id":353525,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-14T22:08:54.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":113,"price":300.39,"value":33944.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79)."}],"balance_after":61915,"source":{"system":"sec-edgar","filing":"0001209191-23-009232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009232/doc4.xml","form_type":"4"}},{"id":353524,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-14T22:08:54.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":4340,"price":298.26,"value":1294448.4,"ownership":{"direct":true},"balance_after":62028,"source":{"system":"sec-edgar","filing":"0001209191-23-009232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009232/doc4.xml","form_type":"4"}},{"id":353523,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-14T22:08:54.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":902,"price":294.33,"value":265485.66,"ownership":{"direct":true},"balance_after":66368,"source":{"system":"sec-edgar","filing":"0001209191-23-009232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009232/doc4.xml","form_type":"4"}},{"id":354144,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-03T21:58:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":67270,"source":{"system":"sec-edgar","filing":"0001209191-23-006980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006980/doc4.xml","form_type":"4"}},{"id":354143,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-03T21:58:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":12314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":59404,"source":{"system":"sec-edgar","filing":"0001209191-23-006980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006980/doc4.xml","form_type":"4"}},{"id":354142,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-03T21:58:27.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":9092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 03/01/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":47090,"source":{"system":"sec-edgar","filing":"0001209191-23-006980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006980/doc4.xml","form_type":"4"}},{"id":354213,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2023-02-02T21:18:08.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":106,"price":325,"value":34450.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."}],"balance_after":37998,"source":{"system":"sec-edgar","filing":"0001209191-23-006215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006215/doc4.xml","form_type":"4"}},{"id":356978,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":22,"price":317.77,"value":6990.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $317.77 (range $317.56 to $317.82)."}],"balance_after":38104,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356977,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":10,"price":315.68,"value":3156.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."}],"balance_after":38126,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356976,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":12,"price":314.43,"value":3773.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $314.43 (range $314.42 to $314.48)."}],"balance_after":38136,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356975,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":81,"price":313.37,"value":25382.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $313.37 (range $312.98 to $313.97)."}],"balance_after":38148,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356974,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":100,"price":312.4,"value":31240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $312.40 (range $311.98 to $312.90)."}],"balance_after":38229,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356973,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":39,"price":311.17,"value":12135.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $311.17 (range $310.51 to $311.45)."}],"balance_after":38329,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356972,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":56,"price":310.1,"value":17365.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $310.10 (range $309.50 to $310.48)."}],"balance_after":38368,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":356971,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-11-03T20:05:18.000Z","date":"2022-11-01","kind":"tax_withholding","acquired":false,"shares":768,"price":312.84,"value":240261.12,"ownership":{"direct":true},"balance_after":38424,"source":{"system":"sec-edgar","filing":"0000899243-22-034883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322034883/doc4.xml","form_type":"4"}},{"id":357272,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-10-20T20:11:40.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":288,"price":301.84,"value":86929.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $301.84 (range $301.14 to $301.98)."}],"balance_after":39192,"source":{"system":"sec-edgar","filing":"0000899243-22-033880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322033880/doc4.xml","form_type":"4"}},{"id":357271,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-10-20T20:11:40.000Z","date":"2022-10-18","kind":"sale","acquired":false,"shares":1503,"price":300.02,"value":450930.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $300.02 (range $300.00 to $300.14)."}],"balance_after":39480,"source":{"system":"sec-edgar","filing":"0000899243-22-033880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322033880/doc4.xml","form_type":"4"}},{"id":359219,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-08-03T20:05:24.000Z","date":"2022-08-01","kind":"tax_withholding","acquired":false,"shares":766,"price":276.62,"value":211890.92,"ownership":{"direct":true},"balance_after":40983,"source":{"system":"sec-edgar","filing":"0000899243-22-027571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322027571/doc4.xml","form_type":"4"}},{"id":2244883,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:40:10.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":18500,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-034092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122034092/doc4.xml","form_type":"4"}},{"id":361359,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-18T20:22:39.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":8,"price":254.44,"value":2035.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $254.44 (range $254.35 to $254.57)."}],"balance_after":41749,"source":{"system":"sec-edgar","filing":"0000899243-22-018605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322018605/doc4.xml","form_type":"4"}},{"id":361358,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-18T20:22:39.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":15,"price":253.99,"value":3809.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $253.99 (range $253.33 to $254.32)."}],"balance_after":41757,"source":{"system":"sec-edgar","filing":"0000899243-22-018605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322018605/doc4.xml","form_type":"4"}},{"id":361357,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-18T20:22:39.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":7,"price":252.43,"value":1767.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $252.43 (range $252.15 to $253.07)."}],"balance_after":41772,"source":{"system":"sec-edgar","filing":"0000899243-22-018605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322018605/doc4.xml","form_type":"4"}},{"id":361356,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-18T20:22:39.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":8,"price":251.37,"value":2010.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $251.37 (range $251.00 to $251.88)."}],"balance_after":41779,"source":{"system":"sec-edgar","filing":"0000899243-22-018605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322018605/doc4.xml","form_type":"4"}},{"id":361355,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-18T20:22:39.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":7,"price":250.56,"value":1753.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $250.56 (range $250.00 to $250.87)."}],"balance_after":41787,"source":{"system":"sec-edgar","filing":"0000899243-22-018605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322018605/doc4.xml","form_type":"4"}},{"id":361745,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-06T20:05:33.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":36,"price":275.09,"value":9903.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $275.09 (range $275.00 to $275.11)."}],"balance_after":41660,"source":{"system":"sec-edgar","filing":"0000899243-22-017086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322017086/doc4.xml","form_type":"4"}},{"id":361906,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":4,"price":264.37,"value":1057.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."}],"balance_after":41696,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361905,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":65,"price":261.79,"value":17016.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $261.79 (range $261.39 to $262.23)."}],"balance_after":41700,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361904,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":23,"price":260.44,"value":5990.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $260.44 (range $260.35 to $261.31)."}],"balance_after":41765,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361903,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":75,"price":259.58,"value":19468.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $259.58 (range $259.24 to $260.07)."}],"balance_after":41788,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361902,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":43,"price":258.46,"value":11113.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $258.46 (range $258.11 to $258.93)."}],"balance_after":41863,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361901,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":90,"price":257.49,"value":23174.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $257.49 (range $257.05 to $257.87)."}],"balance_after":41906,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":361900,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-04T21:10:57.000Z","date":"2022-05-02","kind":"sale","acquired":false,"shares":20,"price":255.47,"value":5109.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $255.47 (range $255.23 to $255.70)."}],"balance_after":41996,"source":{"system":"sec-edgar","filing":"0000899243-22-016641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016641/doc4.xml","form_type":"4"}},{"id":362003,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-05-03T20:26:41.000Z","date":"2022-04-29","kind":"tax_withholding","acquired":false,"shares":766,"price":276.17,"value":211546.22,"ownership":{"direct":true},"balance_after":42016,"source":{"system":"sec-edgar","filing":"0000899243-22-016316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322016316/doc4.xml","form_type":"4"}},{"id":362834,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-08T20:34:51.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":30,"price":277.02,"value":8310.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."}],"balance_after":42782,"source":{"system":"sec-edgar","filing":"0000899243-22-014360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014360/doc4.xml","form_type":"4"}},{"id":362833,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-08T20:34:51.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":327,"price":276.39,"value":90379.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $276.39 (range $276.00 to $276.78)."}],"balance_after":42812,"source":{"system":"sec-edgar","filing":"0000899243-22-014360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014360/doc4.xml","form_type":"4"}},{"id":362832,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-08T20:34:51.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":204,"price":275.71,"value":56244.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $275.71 (range $275.00 to $275.95)."}],"balance_after":43139,"source":{"system":"sec-edgar","filing":"0000899243-22-014360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014360/doc4.xml","form_type":"4"}},{"id":362910,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-06T21:02:38.000Z","date":"2022-04-05","kind":"sale","acquired":false,"shares":3163,"price":275.23,"value":870552.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $275.23 (range $275.00 to $275.66)."}],"balance_after":43343,"source":{"system":"sec-edgar","filing":"0000899243-22-014120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014120/doc4.xml","form_type":"4"}},{"id":362909,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-06T21:02:38.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":257,"price":268.43,"value":68986.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78)."}],"balance_after":46506,"source":{"system":"sec-edgar","filing":"0000899243-22-014120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014120/doc4.xml","form_type":"4"}},{"id":362908,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-06T21:02:38.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":305,"price":267.1,"value":81465.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57)."}],"balance_after":46763,"source":{"system":"sec-edgar","filing":"0000899243-22-014120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014120/doc4.xml","form_type":"4"}},{"id":363066,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-04-05T20:05:47.000Z","date":"2022-04-01","kind":"tax_withholding","acquired":false,"shares":1344,"price":263.09,"value":353592.96,"ownership":{"direct":true},"balance_after":47068,"source":{"system":"sec-edgar","filing":"0000899243-22-013705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322013705/doc4.xml","form_type":"4"}},{"id":363615,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-03-21T20:10:21.000Z","date":"2022-03-17","kind":"sale","acquired":false,"shares":2122,"price":250.06,"value":530627.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $250.06 (range $250.00 to $250.48)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":48412,"source":{"system":"sec-edgar","filing":"0000899243-22-011701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322011701/doc4.xml","form_type":"4"}},{"id":365560,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-22T22:02:23.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":3439,"price":232.51,"value":799601.89,"ownership":{"direct":true},"balance_after":50534,"source":{"system":"sec-edgar","filing":"0000899243-22-007215","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007215/doc4.xml","form_type":"4"}},{"id":366084,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-14T21:21:21.000Z","date":"2022-02-10","kind":"tax_withholding","acquired":false,"shares":979,"price":237.74,"value":232747.46,"ownership":{"direct":true},"balance_after":53973,"source":{"system":"sec-edgar","filing":"0001209191-22-009245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122009245/doc4.xml","form_type":"4"}},{"id":366656,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":16,"price":254.54,"value":4072.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80)."}],"balance_after":54952,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366655,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":64,"price":253.95,"value":16252.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42)."}],"balance_after":54968,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366654,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":149,"price":253.07,"value":37707.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42)."}],"balance_after":55032,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366653,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":141,"price":251.47,"value":35457.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85)."}],"balance_after":55181,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366652,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":670,"price":250.04,"value":167526.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":55322,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366651,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-01","kind":"tax_withholding","acquired":false,"shares":526,"price":243.64,"value":128154.64,"ownership":{"direct":true},"balance_after":55992,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366650,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":12314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit award that vests in installments beginning on 02/24/2023."}],"balance_after":56518,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":366649,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2022-02-03T21:26:09.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":11628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022."}],"balance_after":44204,"source":{"system":"sec-edgar","filing":"0001209191-22-006792","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006792/doc4.xml","form_type":"4"}},{"id":369885,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-11-03T20:09:18.000Z","date":"2021-11-01","kind":"tax_withholding","acquired":false,"shares":766,"price":185.07,"value":141763.62,"ownership":{"direct":true},"balance_after":32576,"source":{"system":"sec-edgar","filing":"0001209191-21-062676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121062676/doc4.xml","form_type":"4"}},{"id":372838,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-08-03T20:10:14.000Z","date":"2021-07-30","kind":"tax_withholding","acquired":false,"shares":766,"price":200.39,"value":153498.74,"ownership":{"direct":true},"balance_after":33342,"source":{"system":"sec-edgar","filing":"0001209191-21-049288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121049288/doc4.xml","form_type":"4"}},{"id":375220,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-05-19T20:10:50.000Z","date":"2021-05-17","kind":"sale","acquired":false,"shares":47,"price":216.88,"value":10193.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $216.88 (range $216.44 to $217.21)."}],"balance_after":34108,"source":{"system":"sec-edgar","filing":"0001209191-21-033992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121033992/doc4.xml","form_type":"4"}},{"id":375219,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-05-19T20:10:50.000Z","date":"2021-05-17","kind":"sale","acquired":false,"shares":65,"price":215.95,"value":14036.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.32)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":34155,"source":{"system":"sec-edgar","filing":"0001209191-21-033992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121033992/doc4.xml","form_type":"4"}},{"id":375975,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-05-06T01:23:50.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":459,"price":218.83,"value":100442.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $218.83 (range $218.52 to $219.24)."}],"balance_after":34108,"source":{"system":"sec-edgar","filing":"0001209191-21-030522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121030522/doc4.xml","form_type":"4"}},{"id":375974,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-05-06T01:23:50.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":501,"price":218.06,"value":109248.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $218.06 (range $217.51 to $218.49)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":34567,"source":{"system":"sec-edgar","filing":"0001209191-21-030522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121030522/doc4.xml","form_type":"4"}},{"id":375973,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-05-06T01:23:50.000Z","date":"2021-04-30","kind":"tax_withholding","acquired":false,"shares":766,"price":217.21,"value":166382.86,"ownership":{"direct":true},"balance_after":35068,"source":{"system":"sec-edgar","filing":"0001209191-21-030522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121030522/doc4.xml","form_type":"4"}},{"id":2730299,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T23:25:53.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":1172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in thirty-six (36) equal monthly installments beginning December 1, 2020."}],"balance_after":1172,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":1172},"source":{"system":"sec-edgar","filing":"0001209191-21-030101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121030101/doc4.xml","form_type":"4"}},{"id":2730298,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T23:25:53.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":18500,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-21-030101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121030101/doc4.xml","form_type":"4"}},{"id":376937,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-04-07T20:04:19.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":389,"price":214.99,"value":83631.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $214.99 (range $214.76 to $215.20)."}],"balance_after":35834,"source":{"system":"sec-edgar","filing":"0001209191-21-025841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121025841/doc4.xml","form_type":"4"}},{"id":376936,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-04-07T20:04:19.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":1297,"price":213.89,"value":277415.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $213.89 (range $213.40 to $214.25)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":36223,"source":{"system":"sec-edgar","filing":"0001209191-21-025841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121025841/doc4.xml","form_type":"4"}},{"id":377067,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-04-05T20:02:50.000Z","date":"2021-04-01","kind":"tax_withholding","acquired":false,"shares":1344,"price":214.16,"value":287831.04,"ownership":{"direct":true},"balance_after":37520,"source":{"system":"sec-edgar","filing":"0001209191-21-025105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121025105/doc4.xml","form_type":"4"}},{"id":380317,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-02-16T21:22:56.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":217,"price":211.41,"value":45875.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $211.41 (range $211.17 to $211.50)."}],"balance_after":38864,"source":{"system":"sec-edgar","filing":"0001209191-21-010733","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121010733/doc4.xml","form_type":"4"}},{"id":380316,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-02-16T21:22:56.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":1469,"price":210.44,"value":309136.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $210.44 (range $210.06 to $210.90)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":39081,"source":{"system":"sec-edgar","filing":"0001209191-21-010733","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121010733/doc4.xml","form_type":"4"}},{"id":380486,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15353,"kind":"person","name":"Sanna Bastiano","position":1,"cik":"0001829069","reported_name":"Sanna Bastiano","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Cell & Genetic Therapies"}}],"security":"Common Stock","published_at":"2021-02-12T21:14:50.000Z","date":"2021-02-10","kind":"tax_withholding","acquired":false,"shares":1344,"price":214.16,"value":287831.04,"ownership":{"direct":true},"balance_after":40550,"source":{"system":"sec-edgar","filing":"0001209191-21-010118","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121010118/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-12T21:14:50.000000Z,380486"}